May 30, 2025

Excellence Strategy: HITS researchers successful with two clusters on astrophysics and life sciences

Excellence Strategy: HITS researchers successful with two clusters on astrophysics and life sciences

How do stellar explosions or the evolution of galaxies influence our universe today? How can synthetic biology and specially designed cells aid in the protection of our immune system against infections and cancer? Tackling these research questions from different disciplines is the endeavor of two projects that have been selected as Clusters of Excellence in the Excellence Strategy of the Federal and State Governments of Germany. Both of these projects involve researchers from the Heidelberg Institute for Theoretical Studies (HITS).

Kai Polsterer (Photo: HITS)

“Together with our partners, we are delighted with this success,” says Kai Polsterer, current Scientific Director at HITS. “The approval for two clusters validates our work, which is based on interdisciplinary thought and a deep understanding of basic research.” The physicist and computer scientist is himself a major contributor in one of the Clusters of Excellence.

In “Dynaverse”, his team will work towards understanding the dynamic processes in the universe across a wide range of time scales.

Rebecca Wade (Photo: HITS)

Biophysicist Rebecca Wade runs a sub-project at “SynthImmune – Engineering Immune Function with Synthetic Biology” and provides expertise in molecular modeling and computer simulation.

Former HITS group leader Frauke Gräter, who since January 2025 has been working as Director at the Max Planck Institute for Polymer Research in Mainz, is part of another approved Cluster of Excellence at Heidelberg University, “3D Matter Made to Order”.

Excellence Strategy

The Excellence Strategy aims to enhance Germany’s status as an outstanding research hub for science as well as enrich its international competitiveness. It encourages the successful development of German universities by financially supporting research of the highest standard, training top performers in research, and facilitating collaboration between universities and across scientific disciplines.

Media Contact:

Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies (HITS)

About HITS

HITS, the Heidelberg Institute for Theoretical Studies, was established in 2010 by physicist and SAP co-founder Klaus Tschira (1940-2015) and the Klaus Tschira Foundation as a private, non-profit research institute. HITS conducts basic research in the natural, mathematical, and computer sciences. Major research directions include complex simulations across scales, making sense of data, and enabling science via computational research. Application areas range from molecular biology to astrophysics. An essential characteristic of the Institute is interdisciplinarity, implemented in numerous cross-group and cross-disciplinary projects. The base funding of HITS is provided by the Klaus Tschira Foundation.

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp